Targeted Therapy Combination Shows Promising Antitumor Activity in Aggressive Meningiomas
PHILADELPHIA — The targeted therapy combination of the mTOR inhibitor everolimus (Afinitor) and the somatostatin agonist octreotide (Sandostatin) yielded...
Search/Filter
Loading...
Adolescent and Young Adult Cancer Survivors May Have an Elevated Risk of Hospitalizations
PHILADELPHIA — Adolescent and young adults who survived at least two years after a cancer diagnosis had nearly double...
New AACR Journal, Blood Cancer Discovery, Publishes Its First Paper
Study reports the landscape of mutations present in pediatric acute lymphoblastic leukemia (ALL) and how this landscape changes during...
American Cancer Survivors Face Substantial Financial Hardship and Financial Sacrifices
PHILADELPHIA —American cancer survivors, particularly those 64 years or younger, faced substantial medical financial hardship and sacrifices in spending,...
Circulating Tumor DNA May Be Predictive of Disease Progression in Patients with Rectal Cancer
PHILADELPHIA — Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemoradiotherapy was associated with poor response and increased risk...
The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer Research
PHILADELPHIA, PA and CAMBRIDGE, MA – Two grants for research that could transform cancer therapies have been funded through...
The AACR and St. Baldrick’s Foundation Partner on a New Scientific Achievement Award and Grant to Support Pediatric Cancer Research
The American Association for Cancer Research and the St. Baldrick’s Foundation are pleased to announce the creation of the AACR-St....
Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer
Study also indicated that a lack of ctDNA may signal improved outcomes for patients SAN ANTONIO — The presence...
Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type
SAN ANTONIO — A large meta-analysis of breast cancer patients showed that residual cancer burden after neoadjuvant chemotherapy is...
Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial
SAN ANTONIO — Metastatic breast cancer patients who received an oral formulation of the chemotherapy drug paclitaxel had better...